Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — LD Micro Conference 2010
54 slides from Aethlon Medical's conference presentation, Dec 10, 2010
Slide 1: LD Micro Conference, Jim Joyce, Chairman and CEO
December 9, 2010 JIM JOYCE CHAIRMAN, CEO LD MICRO CONFERENCE
Slide 2: Forward looking statements
Forward looking statements MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR PRODUCTS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS
Slide 3: Available Conference Documents
Available Conference Documents “A Platform Technology to Address Bioterrorism” ¤ 11/18/10 Shareholder Letter ¤ 12/1/10 California Equity Research Initiation ¤ 12/8/10
Slide 4: We create revolutionary devices that address infectious disease and cancer
WE CREATE REVOLUTIONARY DEVICES THAT ADDRESS INFECTIOUS DISEASE & CANCER
Slide 5: The first medical device to filter viruses and immunosuppressive particles
THE FIRST MEDICAL DEVICE TO FILTER VIRUSES AND IMMUNOSUPPRESSIVE PARTICLES FROM CIRCULATION THE HEMOPURIFIER® SELECTIVELY
Slide 6: Leveraging Established Infrastructure
Leveraging Established Infrastructure
Slide 7: Subtractive Therapy Selectively Targets the Removal of
Subtractive Therapy Selectively Targets the Removal of:
Slide 8: Medical Device vs. Biologic Regulatory Pathway
MEDICAL DEVICE VS. BIOLOGIC REGULATORY PATHWAY
Slide 9: Treatment Experiences in Humans
70 TREATMENT EXPERIENCES IN HUMANS
Slide 10: Substantial viral load reduction in HIV and HCV infected individuals
SUBSTANTIAL VIRAL LOAD REDUCTION IN HIV AND HCV INFECTED INDIVIDUALS
Slide 11: Leading broad-spectrum countermeasure against bioterror and pandemic threats
LEADING BROAD- SPECTRUM COUNTERMEASURE AGAINST BIOTERROR & PANDEMIC THREATS
Slide 12: Near-term commercialization pathway overseas
NEAR-TERM COMMERCIALIZATION PATHWAY OVERSEAS
Slide 13: IDE on file with the FDA
IDE ON FILE WITH THE FDA
Slide 14: GMP manufacturing established through partnership with NextPharma Technologies
GMP MANUFACTURING ESTABLISHED THROUGH PARTNERSHIP WITH NEXTPHARMA TECHNOLOGIES
Slide 15: LOI signed with Membrana for large-scale production
LOI SIGNED WITH MEMBRANA FOR LARGE-SCALE PRODUCTION
Slide 16: Hemopurifier provides a pipeline into three multi-billion markets
HEMOPURIFIER® PROVIDES A PIPELINE INTO THREE $ MULTI- BILLION MARKETS
Slide 17: * 180m infected
* 180m infected * $4.A4bn in 2009 * $9.1 bn in 2015 * 33m infected * $12bn in 2009 * $13.7bn in 2016 * 12m new cases/yr * 7m deaths/yr * $50bn in 2008 ¢ $110bn in 2013
Slide 18: Our wildcard market opportunity
OUR WILDCARD MARKET OPPORTUNITY
Slide 19: The most advanced broad-spectrum countermeasure for bioterror and pandemic threats
The Most Advanced Broad-Spectrum Countermeasure Bioterror & Pandemic Threats
Slide 20: Virus collaborators and human variety
Virus Collaborators Human Variety Ebola CDC / USAMRIID YES Dengue NIV / WHO YES Lassa SFBR YES West Nile Battelle YES H5N1 Avian Battelle YES Spanish Flu of 1918-R Battelle YES 2009 H1N1 Swine Battelle YES Monkey pox Battelle NO
Slide 21: Quote from Ken Alibek on the Hemopurifier
“The Hemopurifier® is the only strategy to address the breadth of pathogens that could be weaponized as agents of bioterror” Ken Alibek
Slide 22: Our primary market focus is
OUR PRIMARY MARKET FOCUS IS…..
Slide 23: Hepatitis-C Virus (HCV)
Hepatitis-C Virus (HCV) TO ACCELERATE EARLY VIRAL LOAD REDUCTION OF HCV STANDARD OF CARE (SOC) DRUG THERAPY
Slide 24: In the absence of drug therapy
IN THE ABSENCE OF DRUG THERAPY
Slide 25: One week study - three Hemopurifier treatments
ONE WEEK STUDY - THREE HEMOPURIFIER® TREATMENTS 5 Day HCV Treatment Studies
Slide 26: Combine Hemopurifier with HCV-SOC to accelerate early viral depletion
OUR STRATEGY IS TO COMBINE OUR HEMOPURIFIER® WITH HCV- SOC TO ACCELERATE EARLY VIRAL DEPLETION
Slide 27: Viral filtration has been proven to improve HCV cure rates
VIRAL FILTRATION HAS BEEN PROVEN TO IMPROVE HCV CURE RATES!
Slide 28: Validation for Viral Filtration Therapy
Success % Validation for Viral Filtration Therapy
Slide 29: An Enduring Adjunct Opportunity
An Enduring Adjunct Opportunity ¨ Hemopurifier® + Current SOC ¨ Hemopurifier® + Future Iterations of SOC ¤ 65 drugs in competition
Slide 30: The Hemopurifier + HCV SOC Study
The Hemopurifier® + HCV SOC Study ¨ Enrollment has been initiated at the Medicity ¨ Up to 30 Patients ¨ Up to 6 treatments in first 3 days of SOC ¨ Clinical endpoints include: ¤ Immediate Virologic Response (IVR) ¤ Rapid Virologic Response (RVR) ¤ Early Virologic Response (EVR) ¨ Positive outcomes t
Slide 31: Human Immunodeficiency Virus (HIV)
Human Immunodeficiency Virus (HIV) OUR HEMOPURIFIER® IS THE ONLY TREATMENT STRATEGY TO ADDRESS DRUG RESISTANT AIDS PATIENTS
Slide 32: Do HIV infected individuals have to die when they no longer respond to their meds?
DO HIV INFECTED INDIVIDUALS HAVE TO DIE WHEN THEY NO LONGER RESPOND TO THEIR MEDS?
Slide 33: In the absence of drug therapy
IN THE ABSENCE OF DRUG THERAPY
Slide 34: HIV/AIDS Patient Data
92% reduction of viral load Improved CD4+ T-cell % 30 DAY STUDY - THREE HEMOPURIFIER® TREATMENTS PER WEEK AIDS HIV/AIDS Patient Data
Slide 35: If you have cancer
IF YOU HAVE CANCER …………
Slide 36: Exosomes are secreted by all tumors, lymphomas and leukemias
EXOSOMES ARE SECRETED BY ALL TUMORS, LYMPHOMAS, & LEUKEMIAS
Slide 37: Exosomes are Immunosuppressive
Exosomes are Immunosuppressive ¨ Induce Apoptosis ¨ Disrupt T-Cell Signaling ¨ Inhibit Cytokine Production ¨ Angiogenesis ¨ Metastasis
Slide 38: Tumor exosomes
membrane cosomes tumor ex:
Slide 39: Our Hemopurifier is the sole therapeutic strategy to address immunosuppressive exosomes
OUR HEMOPURIFIER® IS THE SOLE THERAPEUTIC STRATEGY TO ADDRESS IMMUNSUPPRESSIVE EXOSOMES
Slide 40: Goal is to maximize the ability of the immune system to combat cancer
GOAL IS TO MAXIMIZE THE ABILITY OF THE IMMUNE SYSTEM AND/OR OTHER THERAPIES TO COMBAT CANCER?
Slide 41: A Complementary Therapeutic
A Complementary Therapeutic ¨ Targets Benefit w/o ¤ Stacking additional drug toxicity ¤ Adding drug interaction risk
Slide 42: Cancer studies
Slide 43: U.S. Clinical Programs
Ss U.S. Clinical Programs
Slide 44: Recent Additions to the AEMD Team
Recent Additions to the AEMD Team
Slide 45: Fabiani & Company engaged to reestablish biodefense and pandemic threat programs
September 3rd FABIANI & COMPANY ENGAGED TO REESTABLISH BIODEFENSE & PANDEMIC THREAT PROGRAMS
Slide 46: Miriam Provost named U.S. regulatory advisor
October 26th MIRIAM PROVOST NAMED U.S. REGULATORY ADVISOR
Slide 47: Miriam Provost
Miriam Provost ¨ 13 Years at FDA-ODE ¤ Deputy Director ¤ Division Director ¤ Branch Chief
Slide 48: Rod Kenley named President
October 28th ROD KENLEY NAMED PRESIDENT
Slide 49: Rod Kenley
Rod Kenley ¨ BAXTER ¤ Conceived the HomeChoice Peritoneal Dialyzer n International Marketing Manager n Director of Worldwide Product Planning n Director of Advanced Product Development ¨ AKSYS LTD ¤ Founder ¤ Commercialized the PHD System, the first daily home hemodialysis machine ¨ DEKA RESEARCH
Slide 50: The HomeChoice Device
The HomeChoice® Device
Slide 51: Create a portable Hemopurifier to deliver in-home benefit
CREATE A PORTABLE HEMOPURIFIER® TO DELIVER IN-HOME BENEFIT
Slide 52: Selected 2011 Milestone Targets
Selected 2011 Milestone Targets ¨ HCV TREATMENT DATA ¨ HCV Commercialization ¨ Approval to Initiate U.S. Studies ¨ Clinical Partners Established in EU ¨ Multiple Bioterror Contract/Grant Submissions ¨ Cancer ¤ Data from multiple studies ¤ Disclosure of collaborative partnerships ¨ Advance Mobile/In
Slide 53: Creating revolutionary devices that address infectious disease and cancer
CREATING REVOLUTIONARY DEVICES THAT ADDRESS INFECTIOUS DISEASE & CANCER
Slide 54: Jim Joyce, Chairman, CEO
JIM JOYCE CHAIRMAN, CEO 8910 UNIVERSITY CENTER LANE SAN DIEGO, CA. 92122 JJ@AETHLONMEDICAL.COM 858.459.7800 X301 ASSISTANT: CHARLENE OWEN COWEN@AETHLONMEDICAL.COM 858.459.7800 X305